Intercept Pharmaceuticals Probability of Future Stock Price Finishing Over 19.00

ICPTDelisted Stock  USD 19.00  0.00  0.00%   
Intercept Pharmaceuticals' future price is the expected price of Intercept Pharmaceuticals instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Intercept Pharmaceuticals performance during a given time horizon utilizing its historical volatility. Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
  
Please specify Intercept Pharmaceuticals' target price for which you would like Intercept Pharmaceuticals odds to be computed.

Intercept Pharmaceuticals Target Price Odds to finish over 19.00

The tendency of Intercept Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 19.00 90 days 19.00 
about 13.21
Based on a normal probability distribution, the odds of Intercept Pharmaceuticals to move above the current price in 90 days from now is about 13.21 (This Intercept Pharmaceuticals probability density function shows the probability of Intercept Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.07 . This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Intercept Pharmaceuticals will likely underperform. Moreover Intercept Pharmaceuticals has an alpha of 1.1232, implying that it can generate a 1.12 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
   Intercept Pharmaceuticals Price Density   
       Price  

Predictive Modules for Intercept Pharmaceuticals

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Intercept Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Intercept Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
19.0019.0019.00
Details
Intrinsic
Valuation
LowRealHigh
14.2414.2420.90
Details
Naive
Forecast
LowNextHigh
20.8420.8420.84
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
18.9518.9919.02
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Intercept Pharmaceuticals. Your research has to be compared to or analyzed against Intercept Pharmaceuticals' peers to derive any actionable benefits. When done correctly, Intercept Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Intercept Pharmaceuticals.

Intercept Pharmaceuticals Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Intercept Pharmaceuticals is not an exception. The market had few large corrections towards the Intercept Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Intercept Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Intercept Pharmaceuticals within the framework of very fundamental risk indicators.
α
Alpha over NYSE Composite
1.12
β
Beta against NYSE Composite2.07
σ
Overall volatility
4.03
Ir
Information ratio 0.12

Intercept Pharmaceuticals Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Intercept Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Intercept Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Intercept Pharmaceuticals is not yet fully synchronised with the market data
Intercept Pharmaceuticals has a very high chance of going through financial distress in the upcoming years
Intercept Pharmaceuticals has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
The company reported the previous year's revenue of 285.71 M. Net Loss for the year was (174.86 M) with profit before overhead, payroll, taxes, and interest of 284.73 M.
Intercept Pharmaceuticals currently holds about 404.78 M in cash with (26.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.58.
Over 81.0% of the company shares are owned by institutional investors

Intercept Pharmaceuticals Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Intercept Stock often depends not only on the future outlook of the current and potential Intercept Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Intercept Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding33.8 M
Cash And Short Term Investments490.9 M

Intercept Pharmaceuticals Technical Analysis

Intercept Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Intercept Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Intercept Pharmaceuticals. In general, you should focus on analyzing Intercept Stock price patterns and their correlations with different microeconomic environments and drivers.

Intercept Pharmaceuticals Predictive Forecast Models

Intercept Pharmaceuticals' time-series forecasting models is one of many Intercept Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Intercept Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Intercept Pharmaceuticals

Checking the ongoing alerts about Intercept Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Intercept Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Intercept Pharmaceuticals is not yet fully synchronised with the market data
Intercept Pharmaceuticals has a very high chance of going through financial distress in the upcoming years
Intercept Pharmaceuticals has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
The company reported the previous year's revenue of 285.71 M. Net Loss for the year was (174.86 M) with profit before overhead, payroll, taxes, and interest of 284.73 M.
Intercept Pharmaceuticals currently holds about 404.78 M in cash with (26.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.58.
Over 81.0% of the company shares are owned by institutional investors
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Other Consideration for investing in Intercept Stock

If you are still planning to invest in Intercept Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intercept Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Content Syndication
Quickly integrate customizable finance content to your own investment portal